Therapeutic value of levocabastine eye drops in the treatment of allergic conjunctivitis, a comparative study versus antazoline-tetrahydrozoline eye drops / Jacinto U. Dy-Liacco [and four others]
Subject(s): Abstract: This double-blind comparative study was done to assess and compare the efficacy and safety of levocabastine eye drops in Filipino patients having allergic conjunctivitis versus those of antazoline-tetrahydrozoline eye drops. A total of 54 children and adult were randomized to receive either levocabastine eye drops 0.5 mg/mL administered twice daily or antazoline (0.5 mg/mL)- tetrahydrozoline (0.4 mg/mL) administered four times a day with a treatment duration of two weeks. The patients were classified, depending on the severity of the signs and symptoms of their allergic conjunctivitis, into three categories namely: mild, moderate, and severe. Global evaluation of treatment was rated as excellent, good, moderate or unsatisfactory. Overall therapeutic response was found to be comparable for the two treatment groups. There were also no significant differences between the adverse reactions arising from both drugs. In conclusion, levocabastine is as safe and effective as antazoline-tetrahydrozoline for the treatment of allergic conjunctivitis with its additional advantages of having a faster onset of action and lesser frequency of administration.| Cover image | Item type | Current library | Home library | Collection | Shelving location | Call number | Materials specified | Vol info | URL | Copy number | Status | Notes | Date due | Barcode | Item holds | Item hold queue priority | Course reserves | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Journal Article
|
DOH Central Library Electronic Resource Section | J000168 (Browse shelf(Opens below)) | Available | D0001J000168 |
Browsing DOH Central Library shelves,Shelving location: Electronic Resource Section Close shelf browser (Hides shelf browser)
This double-blind comparative study was done to assess and compare the efficacy and safety of levocabastine eye drops in Filipino patients having allergic conjunctivitis versus those of antazoline-tetrahydrozoline eye drops. A total of 54 children and adult were randomized to receive either levocabastine eye drops 0.5 mg/mL administered twice daily or antazoline (0.5 mg/mL)- tetrahydrozoline (0.4 mg/mL) administered four times a day with a treatment duration of two weeks. The patients were classified, depending on the severity of the signs and symptoms of their allergic conjunctivitis, into three categories namely: mild, moderate, and severe. Global evaluation of treatment was rated as excellent, good, moderate or unsatisfactory. Overall therapeutic response was found to be comparable for the two treatment groups. There were also no significant differences between the adverse reactions arising from both drugs. In conclusion, levocabastine is as safe and effective as antazoline-tetrahydrozoline for the treatment of allergic conjunctivitis with its additional advantages of having a faster onset of action and lesser frequency of administration.
Acta Medica Philippina,1997 33 ( 3 ) pages 157-164
There are no comments on this title.